(Q44388455)

2 December 2017

title

Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis (English)

1 reference

Mycobacterium tuberculosis

2 December 2017

main subject

0 references

1 reference

Juan Carlos Rodriguez Díaz

1

1 reference

2 December 2017

M Ruiz

2

1 reference

2 December 2017

M López

3

1 reference

2 December 2017

G Royo

4

1 reference

2 December 2017

publication date

1 April 2003

1 reference

International Journal of Antimicrobial Agents

2 December 2017

published in

1 reference

2 December 2017

volume

21

1 reference

2 December 2017

issue

4

1 reference

2 December 2017

page(s)

354-356

1 reference

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Clinically significant drug interactions with antituberculosis agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Antimicrobial agent resistance in mycobacteria: molecular genetic insights.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Synergic activity of teicoplanin and ethambutol against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Selective malabsorption and the origin of mono-rifampin-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Tuberculosis and HIV infection: global perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Combined effect of pyrazinamide and ofloxacin within the human macrophage

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900387-4

7 January 2021

10.1016/S0924-8579(02)00387-4

Identifiers

DOI

1 reference

2 December 2017

1 reference